Immune Response Sponsored by the U.S. National Inst.?! - 500 Beiträge pro Seite

[can2]

Strong Buy? Das sind doch hammer News oder nicht? Wenn die 5 Jahre gefördert werden von der US Regierung? Denkt an Geron! Die haben 44 Mio Aktien am Markt, da ist doch die Frage wie tief kann es noch gehen?

March 29, 2005

The Immune Response Corporation Announces That REMUNE® Has Been Selected For A New HIV Clinical Trial Sponsored by The U.S. National Institutes of Health

Carlsbad, California – March 29, 2005 -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis, announced today that the Company’s lead HIV product candidate, REMUNE® (gp120-depleted HIV-1 immunogen), will be included in a clinical trial funded by the U.S. National Institutes of Health (NIH). The NIH trial is designed to study antiretroviral therapy (ART) alone versus ART with a therapeutic HIV immunization, REMUNE®, in recently HIV-infected people. The study is expected to provide important information about the development of HIV disease and the protective role the immune system may play against HIV disease.

“We are excited that REMUNE® has been chosen for this important study which is designed to observe the effects of therapy in early stages of the disease. REMUNE® is the only immune-based therapy to be studied in this trial,” said John N. Bonfiglio, Ph.D., President and Chief Executive Officer of The Immune Response Corporation. “We are pleased that previous demonstrations of the ability of REMUNE® to induce strong new immune responses have led to its inclusion in this trial.”

The Immune Response Corporation’s REMUNE® is an immune-based therapy in development to treat individuals infected by the human immunodeficiency virus (HIV). REMUNE® is different from currently available antiretroviral drug therapies since it is designed to stimulate an HIV-infected individual’s immune system to attack HIV. The Company believes that results of previous clinical trials demonstrate that REMUNE® boosts HIV-specific immune responses and has the potential to slow the progression of HIV infection when used alone or in conjunction with antiretroviral therapy. Furthermore, the Company believes that REMUNE® stimulates the production of specific immune system modulators (cytokines and chemokines) that naturally protect components of the immune system from HIV infection.

“While we have previously studied REMUNE® in both ART-naïve HIV-infected patients and in HIV patients on ART, we believe REMUNE® may also be able to boost HIV-specific immune responses in patients with early stage HIV infection,” said Georgia Theofan, Ph.D., Vice President of Clinical Development at The Immune Response Corporation. “Our own clinical program is expanding to include additional studies in ART-naïve patients with both REMUNE® and IR103, our newest HIV product candidate.”

REMUNE® is in Phase II clinical trial development by The Immune Response Corporation and is not approved by any regulatory agencies in any country at this time.

About the NIH HIV Study

The U.S. National Institutes of Health (NIH) has funded a five-year randomized, controlled clinical trial investigating antiretroviral therapy (ART) alone versus ART with a therapeutic HIV immunization (REMUNE®), both including monitored treatment interruptions, in acute and recently HIV-infected subjects. The study will ultimately enroll 92 patients who will receive currently marketed ART drugs for the first 48 weeks of the study followed by administration of REMUNE® or placebo every 12 weeks for an additional 36 weeks. Patients will also undergo structured treatment interruptions following immunization, and will be followed for a minimum of three years. All patients will be followed with multiple immunologic tests in vitro. The trial will be conducted at NYU Medical Center and the University of Montreal/McGill University AIDS program.

About The Immune Response Corporation

The Immune Response Corporation (Nasdaq: IMNR) is a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS). The Company’s HIV products are based on its patented whole-killed virus technology, co-invented by Company founder Dr. Jonas Salk, to stimulate HIV immune responses. REMUNE®, currently in Phase II clinical trials, is being developed as a first-line treatment for people with early-stage HIV. We have initiated development of a new immune-based therapy, IR103, which incorporates a second-generation immunostimulatory oligonucleotide adjuvant and is currently in Phase I/II clinical trials in Canada and the United Kingdom.

The Immune Response Corporation is also developing an immune-based therapy for MS, NeuroVaxTM, which is currently in Phase II clinical trials and has shown potential therapeutic value for this difficult-to-treat disease.

Please visit The Immune Response Corporation at www.imnr.com

This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE®, NeuroVaxTM or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that REMUNE®, NeuroVaxTM or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE®, NeuroVaxTM or IR103 in preclinical trials and/or earlier clinical trials. These risks, among others, are set forth in The Immune Response Corporation`s SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2004, and its subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.

REMUNE® is a registered trademark of The Immune Response Corporation. NeuroVaxTM is a trademark of The Immune Response Corporation

[chartwaechter]

Womit du recht hast. Ich habe mich reichlich mit 0,41 cent eingedeckt. Das ist eine Aktie die ich schon so lange beobachte und immer mit Gewinn abgestoßen habe.
Ich kann mir einfach nicht vorstellen, dass sie nicht wieder steigt.
Und gute News bietet die Aktie immer dafür, all die Jahre.

[kai.hawaii]

interessant, aber sehr gefährlich.
evtl. run wie aai pharma. warte aber noch ab. die können auf 10 cent fallen oder auf 2 eur steigen. beobachte intensiv.
gruß
kai.hawaii

04.04.2005 17:18
Immune Response: Geld wird knapp
Der Jahresabschlussbericht 2004 von Immune Response (Nachrichten) hat von den unabhängigen Abschlussprüfern das Vermerk „Going Concern“ erhalten. Dies bedeutet, dass die Möglichkeit des Biotech-Unternehmens, im laufenden Jahr seine Verpflichtungen zu erfüllen, in Frage gestellt ist. Aus dem Jahresbericht geht hervor, dass Immune Response auf Schulden im Umfang von 329,8 Millionen Dollar und kurzfristigen Verbindlichkeiten von 6,6 Millionen Dollar sitzt. Dem stehe die Tatsache gegenüber, dass für die absehbare Zukunft keine signifikanten Umsätze zu erwarten seien.

Das Unternehmen selbst legte heute in einer Pflichtmitteilung dar, dass der operative Betrieb durch die derzeitigen Reserven noch bis ins zweite Quartal 2005 abgesichert sei. Man strebe bis dahin an, neue Finanzmittel aufzutreiben.

An der Nasdaq brechen die Titel des Spezialisten für Aids und Multiple Sklerose aktuell um 31,83 Prozent auf 55,9 Cents ein.

[can2]

Hi kai.hawaii,

wie kann das Geld knapp sein, wenn die Regierung fördert? Und wenn die US Regierung investiert, muß da nicht mehr dahinter stecken oder brauchen die lediglich was für die nächste Abschreibung?

Also ich könnte mir schon vorstellen, daß Immune Response auf 0,15 USD oder sonst wohin abstürzen, bei Calypte Bio gings auch erst 3 Monate später ab, als die Rettung kam. Damals hatte ich den größten Teil meines Paketes gekickt,Leiiideeer! Bei OTI ebenfalls, obwohl 2 Fonds eingestiegen sind und gute News vorhanden waren, gings nochmal auf etwa 2 Euro runter und später auf ca. 12 Euro?

Ich kaufe in Schritten, jeden Monat ein paar Stücke dazu, meinetwegen können die auch in OTC gehen, auch dort steigen Aktien, wenn was dahinter steckt. (Biophan, Biocurex...)

Gruß

Can2

[can2]

@chartwaechter
schaue Dir mal den chart von Proxymed an, den habe ich bei mir auf Toilette hängen, darunter steht "Du bist zu dumm, zum Investieren"! (Anika Therapeutics ebenfalls verpennt)

Ich wollte diese Werte kaufen und hatte sie zu lange beobachtet und irgendwann nicht mehr hingeschaut! Der Schock war groß!Heute kaufe ich sofort in mehreren Schritten, hauptsache dabei.

[can2]

04.06.2002
Immune Response spekulativ
Der Aktionär-online

Den Analysten von "Der Aktionär-online" zufolge ist die Aktie von Immune Response (WKN 879428) ein spekulatives Investment.

Eine erst am 30. Mai 2002 veröffentlichte Meldung bezüglich der Wirksamkeit der experimentellen HIV Vakzine in Affen, habe die Herzen der Börsianer höher schlagen lassen und den Aktienkurs der Gesellschaft, die schon seit längerem zu den Penny Stocks gehöre, mit einem Plus von 90,7% in den Börsenhimmel geschickt.

Und was in Affen funktioniere, könnte eventuell auch in seinem nächsten Verwandten dem Menschen funktionieren, weshalb der neue Impfstoff laut Immune Response schon bald erneut am Menschen getestet werden solle. Vielleicht werde dann doch noch gelingen, was in Kooperation mit Pfizer leider gescheitert sei, nämlich die Wirksamkeit des Impfstoffes zu beweisen.

Noch am 30. Mai 2001 sei die Aktie bei 6,10 US-Dollar gehandelt worden, seitdem sei es jedoch sukzessive bergab gegangen, der tiefste Stand von nur noch 33 Cents sei am 22. Mai 2002 erreicht worden. Sollten jedoch die Ergebnisse der geplanten Studie am Menschen ebenso eindeutig ausfallen, wie die in Affen, könnte der Titel vielleicht schon bald wieder auf seinem Höchststand ankommen. Aber vorher müsse der Penny Stock erst einmal das Delisting von der Nasdaq verhindern, weshalb die Aktionäre am 11. Juni 2002 über einen umgekehrten Aktiensplit (1-für-4) abstimmen würden.

Für spekulative Anleger vielleicht die Gelegenheit noch kurz vorher einen kleinen Anteil der Immune Response-Aktien zu erstehen, so die Analysten von "Der Aktionär-online". Vielleicht sehe man ja bereits früher als gedacht den alten Höchststand wieder.

[chartwaechter]

@can2,
ja, es gibt sie die Investitionen die sich einfach nicht realisieren lassen und die verpassten Chancen.
Bei Caly ging es auch einige Zeit rauf und runter, bin dann aber ausgestiegen, weil da einiges schief gelaufen ist.
Aber Immune Response ist anders. Hier wird wirklich Forschung getrieben und es müßte echt schon schief laufen wenn da nicht tatsächlich hier und da gute News kommen die das Papier in die Höhe treiben.
Das Immune von staatlicher Seite unterstützt wird sehe ich eher mit gemischten Gefühlen. Ich denke da steckt viel Politik dahinter, die damit zumindest vorweisen kann, dass sie etwas gegen Aids unternimmt. Wenn der Zeitgeist das aber nicht mehr wil, dann.....
Aber egal, Geld stinkt nicht, also her damit und etwas gutes tun die auch.
Uns allen viel Glück
chartwaechter

[chartwaechter]

Und es hat bummm gemacht. Heute über 30 % plus. Haben wir doch gut gemacht, gell can2
Chartwaechter

[can2]

jep!

[can2]

Börse NASDAQ

Aktuell 0,721 USD

Zeit 20.04.05 21:59

Diff. Vortag -13,13 %

Tages-Vol. 400.849,54

Geh. Stück 568.950



Geld 0,01

Brief 9.000,00

Zeit 20.04.05 00:31

Spread 100%

Geld Stk. 100

Brief Stk. 100



Schluss
Vortag 0,83

Eröffnung 0,80

Hoch 0,88

Tief 0,72

52W Hoch 2,02

52W Tief 0,53

[can2]

zur Zeit keine Action bei Immune was?

[can2]

Viropharma geht auch gut ab, aber schon zu teuer!

June 01, 2005

The Immune Response Corporation Announces IR103 to be Studied in Drug-Naïve HIV Patients

Carlsbad, California – June 1, 2005 -- The Immune Response Corporation (Nasdaq: IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), announced today that a new arm of a Phase I/II clinical trial investigating IR103, the Company’s newest product candidate for the treatment of HIV, has been initiated. This new arm will enroll HIV patients who have not yet begun highly active antiretroviral therapy (HAART) and who will receive IR103, REMUNE®, or saline over 28 weeks. The new drug-naïve arm will enroll at two sites in the United Kingdom and one site in Canada. The study, originated in 2004, has already enrolled 45 HIV patients receiving HAART at the three sites in Canada and Britain.

“We believe IR103 will demonstrate similar results to those we’ve seen in the REMUNE® trials with drug-naïve HIV patients, such as the one recently completed in Italy. Current guidelines recommend delaying HAART treatment in newly diagnosed HIV patients, in part because current treatments are so toxic,” said John N. Bonfiglio, Ph.D., President and Chief Executive Officer of The Immune Response Corporation. “IR103 and REMUNE® may fill this gap by providing an efficacious and safe therapy in these early stages of the disease.”

The randomized, single-blind, controlled, multi-center Phase I/II study began in 2004 and will follow patients for 28 weeks. The primary objective of this study is to evaluate safety and bioactivity, or the ability to generate HIV-specific immune responses to IR103, in HIV patients with and without HAART. Ability to generate HIV-specific immune responses is thought to be an important indicator of clinical utility.

IR103 combines the Company’s patented HIV-1 immunogen with Amplivax™, an immunostimulatory oligonucleotide adjuvant. Amplivax™ was developed by Hybridon, Inc. and has been licensed to The Immune Response Corporation.

About The Immune Response Corporation

The Immune Response Corporation (Nasdaq: IMNR) is a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS). The Company’s HIV products are based on its patented whole-killed virus technology, co-invented by Company founder Dr. Jonas Salk, to stimulate HIV immune responses. REMUNE®, currently in Phase II clinical trials, is being developed as a first-line treatment for people with early-stage HIV. We have initiated development of a new immune-based therapy, IR103, which incorporates a second-generation immunostimulatory oligonucleotide adjuvant and is currently in Phase I/II clinical trials in Canada and the United Kingdom.

The Immune Response Corporation is also developing an immune-based therapy for MS, NeuroVax™, which is currently in Phase II clinical trials and has shown potential therapeutic value for this difficult-to-treat disease.

Please visit The Immune Response Corporation at www.imnr.com

This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of REMUNE®, NeuroVax™ or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that REMUNE®, NeuroVax™ or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of REMUNE®, NeuroVax™ or IR103 in preclinical trials and/or earlier clinical trials. These risks, among others, are set forth in The Immune Response Corporation`s SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2004. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.

REMUNE® is a registered trademark of The Immune Response Corporation. NeuroVax™ is a trademark of The Immune Response Corporation.